The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| 04 August, 2020, 10:18 PM IST | E-Paper
Search
+

    Divya Rajagopal

    Assistant Editor, ET

    Divya Rajagopal is an Assistant Editor with The Economic Times newspaper based out of Mumbai, India. She writes on intersection of medical science and business.

    Articles by the author

    WHO concerned about India's rising Covid-19 cases and the younger lot catching virusWockhardt snags Covid-19 vaccine manufacturing deal from the UK govtAfter reaching their peaks, is it time for Delhi and Mumbai to witness the flattening of covid curve?GAVI in talks to make Indian vaccine makers join Covax: CEO Seth Berkley
    Coronavirus vaccine race: Are human challenge trials ethical? Experts are dividedIndia to play crucial part in global manufacturing of Covid-19 vaccinesTocilizumab fails to improve condition of severe Covid-19 patientsIndian API makers benefit as global buyers ditch China
    Mumbai Sero Survey suggest half of those in slums already infected and recoveredCoronavirus Vaccine Race: Most of the Covid-19 vaccines are already reservedAfter four months, Mumbai private hospitals get ready for non-Covid workSerum Institute founder Cyrus Poonawalla to keep some vaccine aside for Parsis
    Indian entrepreneur’s stake in US vaccine company soars to Rs 400 croreMuch headway in quest for vaccine: Drugmakers might be one step away from the Covid remedyIndian drug companies start off a price war on experimental Covid-19 drugHepatitis C drug can help improve condition of coronavirus patients: Study
    India's keen to join WHO-Gavi vaccine alliance in bid to keep supply cost effectiveSerum Institute can supply 400 million doses by December, says CEO Adar PoonawallaHow are new vaccines developed? Here is the complete processNovartis turning to technology to manage business: Bertrand Bodson, Chief Digital Officer
    Virus may be widespread, but not too lethal, indicate antibody tests at private labsSerum Institute of India to apply for local trials on Oxford's vaccine by AugustFighting the Covid battle: India gets sites ready for Phase-3 vaccine trialsHuman clinical trials of Gennova’s mRNA COVID-19 vaccine to start by the end of this year
    Search for vaccines hots up as Covid-19 continues to spread and wreak havoc around the worldBCG vaccine being tried for Covid-19 elderly individuals in hotspots in IndiaActivists urge India to push for fair allocation of Covid-19 vaccine under COVAXAnthony Fauci cautiously optimistic: Countries need to pull back to contain the spread
    Drug firms get DGCI nod for Covid drug favipiravir despite inconclusive studyBiocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patientsBiocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"Covid-19: The frantic search for a cure continues
    BMC to acquire 20,000 doses of Tocilizumab even as trials yet to determine efficacyImmunologists call for a study on the role of T cells in protecting people against Covid-19Mumbai company working on horse antibodies Covid treatmentNPPA asks Remdisivir drug makers to ensure transparency after complaints about black marketing
    Drug controller asks states to enforce maximum retail price for RemdesivirSanofi halts trials of IL-6 drug for Covid-19, India to continue with trial of another drug of similar classAIIMS, Vizag Hospital yet to approve trials of locally-made Covid vaccineAs demand sputters, ventilator makers want export ban to go
    NIH and DBT to review vaccine candidates for Covid-19 this weekTwo weeks to start the trial, six months at least to finish: ExpertsExperts in two minds over ICMR's August 15 date for Covid-19 vaccine launchDrug makers get nod to raise one-time price increase on heparin injections
    Gilead won't launch its Covid drug in JulyRemdesivir shortage in Maharashtra public hospitalsThere is no need for another nationwide lockdown: ExpertsNo excuse for countries to not do contact tracing: WHO
    ICMR's chief epidemiologist retires, sources say will continue to advise govt in Covid-19 policy decisionsNo excuse for countries to not do contact tracing: WHOLow-cost ventilator maker AgVa asked to upgrade productPositive antibody tests not proof of immunity
    Antibody tests to check immunity to SARS-Cov2 lacks evidence: Raman GangakhedkarThe four front runners of the race for Covid vaccineDrug makers urge Commerce Ministry to clear stuck importsICMR invites cos to develop its anti-serum against Covid
    India Inc sounds out labs for antibody testsMaharashtra asks firms to start antibody tests on their staff, Delhi still to decideCall for patent removal, price cut of Covid-19 drugs and diagnosticsShould policymakers weigh an adjusted Covid death rate?
    Local Covid drug makers ramp up capacityHetero, Cipla to supply generic Remdesivir to hospitals this weekCutting China ties not easy, drug imports up 28% since DoklamCipla, Hetero receive drug controller's emergency approval for Remdesivir for severe Covid-19 patients
    Investments in sports, health bailed me out: Kaustav Ganguly, MD, Alvarez and MarsalFavipiravir and Remdesivir get approval for treatmentRecruitment for HCQ solidarity trial stopped in IndiaIndian drug firms cheer dexamethasone efficacy on severe COVID-19 patients
    How hotspot Mumbai, Delhi can bring down mortalityMumbai sees a ray of hope as recovered outnumber sick'Steroid that costs less than Rs 200 may help prevent Covid-19 deaths'Early detection, isolation helped Dharavi's Covid-19 containment
    Biosimilar drugs can help us reach $1 billion target soon: Christiane Hamacher, CEO, Biocon BiologicsAwaiting critical Remdesivir safety data from companies: DCGIJohnson & Johnson expects nod for Covid vaccine by early 2021: Paul Stoffels, chief scientific officer, J&JMumbai’s private hospitals heave a sigh of relief
    Covid-19: A cure still elusive, but science may find a wayWearing masks can halt spread of virus: StudyCovid-19 diagnostic test makers want export ban lifted as demand for kits from Indian states slow downShortage of nurses cripples Mumbai and New Delhi hospitals
    GSK will price vaccine responsibly: Emmanuel Hanon, R&D HeadIn absence of testing, use clinical criteria to treat suspected covid-19 patients: ExpertsAid organisations, varsities team up to ensure access to cheaper vaccinesTraditional drug companies begin immunity trials
    Maharashtra's plan to buy drug from Bangladesh irks local companiesCOVID-19: Infections rise, so do vaccine trialsAs toll rises, shortage of beds is main worry for Mumbai, DelhiHCQ use unlikely to prevent Covid infection: Study
    AstraZeneca & Serum Institute of India sign licensing deal for 1 billion doses of Oxford vaccineAn almost retracted study on hydroxychloroquine exposes perils of hasty trialsIndian licensees free to price Remdesivir: Gilead
    The Economic Times